Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery ...

In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...

Panelists discuss how ruxolitinib cream demonstrated significant clinical efficacy in treating atopic dermatitis over a 12-month period, with claims analysis revealing improved disease control, ...

John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, pointed to research that has shown a price of $150 ...

Factor XI Inhibitors are the alternative to DOACs, which are highly effective at preventing strokes. However, their bleeding risks often limit their use, especially in high-risk patients.

In an interview with Managed Healthcare Executive, Christian T. Ruff, M.D., M.P.H., director of general cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School, ...

The rate of cardiovascular death, nonfatal heart attack, or nonfatal stroke was 30% lower among patients receiving nurse-led ...

The largest randomized study of fluid intake restrictions showed no benefit from the restrictions, according to its senior ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...